Cargando…

A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer

OBJECTIVES: American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up r...

Descripción completa

Detalles Bibliográficos
Autores principales: Murofushi, Keiko Nemoto, Kitamura, Nozomi, Yoshioka, Yasuo, Sumi, Minako, Ishikawa, Hitoshi, Oguchi, Masahiko, Sakurai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116799/
https://www.ncbi.nlm.nih.gov/pubmed/30044320
http://dx.doi.org/10.1097/IGC.0000000000001305
_version_ 1783351656556003328
author Murofushi, Keiko Nemoto
Kitamura, Nozomi
Yoshioka, Yasuo
Sumi, Minako
Ishikawa, Hitoshi
Oguchi, Masahiko
Sakurai, Hideyuki
author_facet Murofushi, Keiko Nemoto
Kitamura, Nozomi
Yoshioka, Yasuo
Sumi, Minako
Ishikawa, Hitoshi
Oguchi, Masahiko
Sakurai, Hideyuki
author_sort Murofushi, Keiko Nemoto
collection PubMed
description OBJECTIVES: American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up results. METHODS/MATERIALS: The study included 7 patients with vaginal cancer and 14 patients with cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5 mm or less or IBT for vaginal tumors less than 5 mm. Nine patients received ICT and the remaining 12 patients received IBT. For dosimetric comparison, an experimental recalculation as the virtual IBT for patients actually treated by ICT, and vice versa, was performed. RESULTS: The 5-year local control rate for all tumors was 89.4%. No differences in local control between ICT- and IBT-treated groups were observed (P = 0.21). One patient experienced a grade 3 rectal complication. There were no significant differences in the CTV D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the dosimetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT plans exceeded the limited dose for organs at risk, which were recommended in the guideline published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the experimental ICT plans was significantly higher than for the actual IBT plans (P < 0.001 and <0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for bladder and/or rectum D2cc. CONCLUSIONS: Tumor control and toxicity after selected brachytherapy according to vaginal tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc.
format Online
Article
Text
id pubmed-6116799
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61167992018-09-13 A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer Murofushi, Keiko Nemoto Kitamura, Nozomi Yoshioka, Yasuo Sumi, Minako Ishikawa, Hitoshi Oguchi, Masahiko Sakurai, Hideyuki Int J Gynecol Cancer Radiation Therapy OBJECTIVES: American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up results. METHODS/MATERIALS: The study included 7 patients with vaginal cancer and 14 patients with cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5 mm or less or IBT for vaginal tumors less than 5 mm. Nine patients received ICT and the remaining 12 patients received IBT. For dosimetric comparison, an experimental recalculation as the virtual IBT for patients actually treated by ICT, and vice versa, was performed. RESULTS: The 5-year local control rate for all tumors was 89.4%. No differences in local control between ICT- and IBT-treated groups were observed (P = 0.21). One patient experienced a grade 3 rectal complication. There were no significant differences in the CTV D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the dosimetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT plans exceeded the limited dose for organs at risk, which were recommended in the guideline published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the experimental ICT plans was significantly higher than for the actual IBT plans (P < 0.001 and <0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for bladder and/or rectum D2cc. CONCLUSIONS: Tumor control and toxicity after selected brachytherapy according to vaginal tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc. Lippincott Williams & Wilkins 2018-09 2018-07-23 /pmc/articles/PMC6116799/ /pubmed/30044320 http://dx.doi.org/10.1097/IGC.0000000000001305 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of IGCS and ESGO. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Radiation Therapy
Murofushi, Keiko Nemoto
Kitamura, Nozomi
Yoshioka, Yasuo
Sumi, Minako
Ishikawa, Hitoshi
Oguchi, Masahiko
Sakurai, Hideyuki
A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
title A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
title_full A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
title_fullStr A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
title_full_unstemmed A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
title_short A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
title_sort clinical evaluation of american brachytherapy society consensus guideline for bulky vaginal mass in gynecological cancer
topic Radiation Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116799/
https://www.ncbi.nlm.nih.gov/pubmed/30044320
http://dx.doi.org/10.1097/IGC.0000000000001305
work_keys_str_mv AT murofushikeikonemoto aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT kitamuranozomi aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT yoshiokayasuo aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT sumiminako aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT ishikawahitoshi aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT oguchimasahiko aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT sakuraihideyuki aclinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT murofushikeikonemoto clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT kitamuranozomi clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT yoshiokayasuo clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT sumiminako clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT ishikawahitoshi clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT oguchimasahiko clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer
AT sakuraihideyuki clinicalevaluationofamericanbrachytherapysocietyconsensusguidelineforbulkyvaginalmassingynecologicalcancer